MYOV · Myovant Sciences Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $230.97M | $0 | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $107.40M | $136.71M | $192.56M | $222.61M | $116.83M | $43.50M |
| SG&A | $259.36M | $82.33M | $82.33M | $42.22M | $24.23M | $12.36M |
| Total Operating Expenses | - | - | $274.89M | $264.83M | $141.06M | $55.86M |
| D&A | $673.0K | - | $1.76M | $438.0K | $243.0K | $61.0K |
| Operating Income | ($187.35M) | ($274.89M) | ($288.23M) | ($273.07M) | ($143.04M) | ($83.51M) |
| Interest Expense | $13.97M | $12.66M | - | $8.82M | $0 | - |
| Income Tax | $5.05M | $336.0K | $761.0K | $476.0K | $213.0K | ($74.0K) |
| Net Income | ($205.98M) | ($255.13M) | ($288.99M) | ($273.55M) | ($143.25M) | ($83.44M) |
| EPS - Basic | ($3.37) | - | - | - | - | - |
| EPS - Diluted | ($3.37) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $406.70M | $674.49M | $76.64M | $156.07M | $108.62M | $0 |
| Accounts Receivable | $23.30M | $0 | - | - | - | - |
| Inventory | $7.58M | $0 | - | - | - | - |
| Accounts Payable | $12.25M | $17.81M | $15.33M | - | $4.58M | $3.33M |
| Current Assets | $488.14M | $704.64M | $87.91M | $166.79M | $114.76M | $184.16M |
| Total Assets | $520.01M | $725.03M | $105.93M | $172.98M | $119.10M | $185.28M |
| Current Liabilities | $250.33M | $281.34M | $85.92M | $71.97M | $37.09M | $18.34M |
| Long-term Debt | - | - | $0 | $93.24M | $43.62M | - |
| Total Liabilities | $993.49M | $1.08B | $214.20M | $168.64M | $81.37M | $18.50M |
| Stockholders' Equity | ($473.48M) | ($353.96M) | ($108.28M) | $4.33M | $37.73M | $0 |
| Retained Earnings | ($1.25B) | ($1.05B) | ($791.01M) | ($502.02M) | ($228.47M) | ($85.10M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($268.56M) | $370.63M | ($221.17M) | ($224.09M) | ($117.25M) | ($18.21M) |
| Investing Cash Flow | ($18.02M) | ($9.21M) | ($3.94M) | ($1.24M) | ($604.0K) | ($967.0K) |
| Financing Cash Flow | $25.91M | $238.04M | $145.93M | $273.90M | $45.65M | $200.02M |
| CapEx | $974.0K | $1.77M | $1.10M | $1.24M | $604.0K | $967.0K |
| Free Cash Flow | ($269.53M) | $368.86M | ($222.27M) | ($225.32M) | ($117.86M) | ($19.18M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -81.1% | - | - | - | - | - |
| EBITDA margin | -80.8% | - | - | - | - | - |
| Net margin | -89.2% | - | - | - | - | - |
| Free cash flow margin | -116.7% | - | - | - | - | - |
| FCF / Net income | 1.31 | -1.45 | 0.77 | 0.82 | 0.82 | 0.23 |
| R&D / Revenue | 46.5% | - | - | - | - | - |
| SG&A / Revenue | 112.3% | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -39.6% | -35.2% | -272.8% | -158.1% | -120.3% | -45.0% |
| Return on equity | 43.5% | 72.1% | 266.9% | -6311.7% | -379.7% | - |
| Return on invested capital | - | - | - | -221.1% | -138.9% | - |
| Liquidity | ||||||
| Current ratio | 1.95 | 2.50 | 1.02 | 2.32 | 3.09 | 10.04 |
| Quick ratio | 1.92 | 2.50 | 1.02 | 2.32 | 3.09 | 10.04 |
| Cash ratio | 1.62 | 2.40 | 0.89 | 2.17 | 2.93 | 0.00 |
| Leverage | ||||||
| Debt / Equity | - | - | 0.00 | 21.51 | 1.16 | - |
| Debt / Assets | - | - | 0.00 | 0.54 | 0.37 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -13.4x | -21.7x | - | -31.0x | - | - |
| Equity multiplier | -1.10 | -2.05 | -0.98 | 39.91 | 3.16 | - |
| Liabilities / Assets | 1.91 | 1.49 | 2.02 | 0.97 | 0.68 | 0.10 |
| Efficiency | ||||||
| Asset turnover | 0.44 | 0.00 | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 37d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 31.8% | 4.6% | -5.5% | -90.9% | -71.3% | - |
| Net income growth (YoY) | 19.3% | 11.7% | -5.6% | -91.0% | -71.7% | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 1.4% | -91.2% | -514.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -33.8% | -226.9% | - | -88.5% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-03-31.
Product / service
$237.28M totalProduct$94.31M · 39.7%
ORGOVYX$82.96M · 35.0%
License And Service$31.67M · 13.3%
Revenue Recognized Upon Completion Of Delivery$16.70M · 7.0%
MYFEMBREE$6.36M · 2.7%
Richter Product Supply And Royalties$5.00M · 2.1%
RYEQO$300.0K · 0.1%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-2.59
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Myovant Sciences Ltd. against the 5 most active filers in the same SIC group.